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PRIMERS AND PROBE TO IDENTIFY
MYCOBACTERIUM TUBERCULOSIS
COMPLEX

fying MTB complex DNA When used in conjunction With
SEQ ID NO: 2 in a polymerase chain reaction.
Another aspect of the invention relates to an isolated

oligonucleotide of the sequence of SEQ ID NO: 1, Wherein
FIELD OF THE INVENTION

from about one to about three nucleotides are added or

removed from the 5' end and/or from about one to about
three nucleotides are added or removed from the 3' end,

Methods and nucleic acids are disclosed for rapid, reli

respectively, and Wherein the oligonucleotide is capable of
amplifying MTB complex DNA When used in conjunction

able, simple and highly sensitive detection of DNA of the

Mycobacterium tuberculosis (MTB) complex With quanti

With SEQ ID NO: 2 in a polymerase chain reaction.
Another aspect of the invention relates to an isolated
oligonucleotide of the sequence SEQ ID NO: 2.
Another aspect of the invention relates to an isolated

tative real time PCR in formalin-?xed tissues.
BACKGROUND OF THE INVENTION

oligonucleotide that hybridiZes the complement of SEQ ID

Rapid identi?cation of microbial pathogens has long been
an important goal of diagnostic technology. In addition to
identifying the pathogenic species, the clinician must noW
af?rm the potential ef?cacy of standard antimicrobial treat
ments early in the treatment of each case. Delays and
erroneous results associated With conventional diagnostic
tests frequently lead to the administration of ineffective
treatments, Which in turn lead to complications, added costs,

NO: 2 under stringent conditions and is capable of ampli
fying MTB complex DNA When used in conjunction With
SEQ ID NO: 1 in a polymerase chain reaction.
Another aspect of the invention relates to an isolated

oligonucleotide of the sequence of SEQ ID NO: 2, Wherein
20

and poor outcomes.

respectively, and Wherein the oligonucleotide is capable of
amplifying MTB complex DNA When used in conjunction

Tuberculosis (TB) kills 3,000,000 people in the World
every year, more than AIDS, malaria, and other tropical
diseases combined. One third of the World’s population is

25

infected With tuberculosis and it represents more than a

quarter of the World’s preventable deaths. The responsible
mycobacteria are Gram-positive (no outer cell membrane),
non-motile, pleomorphic rods, related to Actinomyces.
Organisms of the Mycobacterium tuberculosis (MTB)
complex are responsible for the signi?cant TB-associated

canetti. M. tuberculosis is the most common MTB complex
pathogen isolated in humans. M bovis BCG may be trans

35

invention the kit further comprises oligonucleotide of the
40

nosis of the disease is important. Classical methods for

identi?cation of mycobacteria rely on staining specimens for
acid fast bacilli folloWed by culture and biochemical testing.
These cumbersome techniques render the identi?cation and

quanti?cation of MTB complex pathogen very inef?cient.
Therefore, although there are reports of PCR-based tests
for diagnosis of TB, there is a continuing need for highly
sensitive assays to rapidly detect the organisms causing TB.
See Park et al., Arch Pathol Lab Med, Vol. 127, March 2003,
pp. 326-330; Brisson-Noel et al., Lancet 1989; 211069-1071;
Beige et al., J. Clin. Microbiol. 1995; 33:90-95; Perosio et
al., Am. J. Clin. Pathol. 1993; 100:643-647; Hardman et al.,
Am. J. Clin. Pathol. 1996; 106:384-389; Salian et al.,Am. J.
Respir. Crit. Care Med. 1998; 158:1150-1155; Vago et al.,
Am. J. Clin. Pathol. 1998; 109:411-415.
All articles and patent documents cited herein are

SEQ ID NO: 3.
Another aspect of the invention relates to a kit for
detecting MTB complex DNA comprising a ?rst isolated
oligonucleotide of SEQ ID NO: 1 or an oligonucleotide
substantially identical thereto and a second oligonucleotide
of SEQ ID NO: 2 or an oligonucleotide substantially iden
tical thereto. In one embodiment of this aspect of the

mitted from infected animals to humans, M. africanum
causes pulmonary tuberculosis in tropical Africa and M
microti primarily infects animals.

Tuberculosis is highly contagious, therefore rapid diag

With SEQ ID NO: 1 in a polymerase chain reaction.
Another aspect of the invention relates to an isolated
oligonucleotide having the sequence of SEQ ID NO: 3 or a

sequence Wherein about one to about three nucleotides are
added or removed from the 5' end and/ or about one to about
30 three nucleotides are added or removed from the 3' end of

morbidity and mortality observed in humans. The TB com

plex consists of the folloWing species: M tuberculosis, M
bovis, M bovis BCG, M. africanum, M microti, and M

from about one to about three nucleotides are added or

removed from the 5' end and/or from about one to about
three nucleotides are added or removed from the 3' end,

sequence of SEQ ID No: 3 or a sequence substantially
identical thereto.
Another aspect of the invention relates to a method of
detecting the presence of MTB complex DNA in a biological

sample comprising; obtaining a biological sample from an
organism; isolating nucleic acids from the sample; perform
45

ing a polymerase chain reaction on the isolated nucleic acids
using as a forWard primer SEQ ID NO: 1 or an oligonucle
otide substantially identical thereto and as a reverse primer
SEQ ID NO: 2 or an oligonucleotide substantially identical
thereto; and correlating a presence of an ampli?cation

50

product from the polymerase chain reaction With the pres
ence of MTB complex DNA in the sample.
Another aspect of the invention relates to an method of

identifying compounds capable of inhibiting groWth of
MTB complex pathogen comprising: infecting a tissue cul
55

ture With an MTB complex pathogen to obtain an infected

tissue culture; contacting a portion of the infected tissue
culture With a compound suspected of being capable of

expressly incorporated by reference for their entirety for all

inhibiting MTB complex pathogen groWth; isolating nucleic

purposes.
SUMMARY OF THE INVENTION

acids from the portion of the infected tissue culture con
tacted by the compound to obtain a ?rst nucleic acid sample
and from a portion of the remainder of the infected tissue
culture not contacted by the compound to obtain a second

One aspect of the invention relates to an isolated oligo
nucleotide of the sequence SEQ ID NO: 1.

nucleic acid sample; performing polymerase chain reaction

60

Another aspect of the invention relates to an isolated

oligonucleotide that hybridiZes the complement of SEQ ID
NO: 1 under stringent conditions and is capable of ampli

65

on the ?rst and the second nucleic acid samples using as a
forWard primer SEQ ID NO: 1 or an oligonucleotide sub
stantially identical thereto and as a reverse primer SEQ ID
NO: 2 or an oligonucleotide substantially identical thereto;

US 7,332,597 B2
3

4

whereby a decrease in an ampli?cation product in the ?rst
nucleic acid sample relative to the second nucleic acid

With the template. A primer need not re?ect the exact

sequence of the template but must be su?iciently comple
mentary to speci?cally hybridiZe With a template. When
primer pairs are referred to herein, the pair is meant to
include one forWard primer Which is capable of hybridiZing

sample indicates that the compound is capable of inhibiting

MTB complex pathogen groWth.
BRIEF DESCRIPTION OF THE DRAWINGS

to the sense strand of a double-stranded target nucleic acid

(the “sense primer”) and one reverse primer Which is
capable of hybridiZing to the antisense strand of a double

FIG. 1. Schematic representation of the study design.
MTB: Mycobaclerium tuberculosis; PCR: polymerase chain

stranded target nucleic acid (the “antisense primer”).

reaction; AFB: acid-fast bacilli.
FIG. 2. Schematic representation of real-time procedure
performed on microdissected formalin-?xed para?in embed
ded (FFPE) tissue sections.

One aspect of the invention relates to oligonucleotide
primers capable of acting as forWard primers in a PCR

reaction for amplifying MTB complex DNA. Preferably, the
forWard primer has the sequence: 5'-GACAACAAAGTTG

FIG. 3. Q-PCR using MTB complex speci?c primers and

GCCACCA-3' (SEQ ID NO: 1).

probe performed on serial dilutions of formalin-?xed MTB
DNA. 4000 to 0.04 pg4one organism equivalent4of DNA
Were used (curves 1-6) as Well as a negative control (curve

Another aspect of the invention relates to oligonucleotide
primers capable of acting as reverse primers in a PCR

7).

reverse primer has the sequence: 5'-TGGGACAACAC

FIG. 4. Q-PCR using MTB complex speci?c primers and
probe performed on atypical mycobacteria (M marinum, M

reaction for amplifying MTB complex DNA. Preferably, the
CTGGAACAA-3' (SEQ ID NO: 2).
20

avium, M cheloneae, M inlracellulare, M kansasii, M
forluilum, M cheloneae subspecies abscessus, M Zerrae, M
gordonae) and human DNA used as negative controls (NC),
and DNA from cases l-3 in FIG. 5, that shoW a positive
result.
FIG. 5. Correlation of Q-PCR results on FFPE tissue
sections positive for acid-fast bacilli and identi?cation of the

Another aspect of the invention relates to oligonucleotide
primers capable of acting as a probe for MTB complex
DNA. Preferably, the probe has the sequence:
5'-TTGGGTCCTGAGGCAACACTCGG-3' (SEQ ID NO:

3).
25

organism by culture.

“Probe” refers to an oligonucleotide Which binds through
complementary base pairing to a sub-sequence of a target
nucleic acid. A primer may be a probe. It Will be understood
by one of skill in the art that probes Will typically substan

tially bind target sequences lacking complete complemen
DETAILED DESCRIPTION OF THE
INVENTION

30

tarity With the probe sequence depending upon the strin
gency of the hybridiZation conditions. The probes are

typically directly labeled (e.g., With isotopes or ?uorescent
The invention relates to oligonucleotides and methods for

the detection of Mycobaclerium tuberculosis complex
(MTB) pathogen in a biological sample. Speci?cally, the

moieties) or indirectly labeled such as With biotin to Which

a streptavidin complex may later bind. By assaying for the
35

presence or absence of the probe, one can detect the pres

oligonucleotides disclosed herein are useful for the ampli

ence or absence of the target, by Southern blot for example.

?cation of MTB DNA in biological samples, particularly in
real-time polymerase chain reactions (PCR) performed on
DNA isolated from formalin-?xed and para?in-embedded
tissue samples. The oligonucleotides and methods disclosed

Preferably, the target is an ampli?cation product generated
by PCR ampli?cation of MTB complex nucleic acids using
primers SEQ ID NOs: l and 2, or oligonucleotides substan
40

herein are superior to those of the prior art because, for
example, they enable the skilled artisan to detect a single
copy of MTB complex DNA in a biological sample.

More, preferably, the probes are ?uorescently labeled and
are capable of acting as a hydrolysis or Taqman® probes in
a real-time PCR reaction to amplify MTB complex nucleic

“Nucleic acid” refers to a deoxyribonucleotide or ribo

nucleotide polymer in either single- or double-stranded
form, and unless otherWise limited, Would encompass

acids. The real-time PCR method uses a dual labelled
45

plate amplicon spanning the forWard (e.g. SEQ ID NO: 1)
and reverse primers (e.g. SEQ ID NO: 2). Preferably, a
?uorescent reporter molecule attached to 5'-position that
50

otides, such as primers, probes, nucleic acid fragments to be
oligonucleotide depends on many factors and the ultimate

that quenches (absorbs) the ?uorescence emission from the
Reporter only When Reporter is attached to the probe before

function or use of the oligonucleotide.
55

nucleotides. Short primer molecules generally require cooler
temperatures to form su?iciently stable hybrid complexes

hydrolysis. Preferably, laser stimulation Within the capped
Wells containing the reaction mixture causes emission of a 3'

quencher dye (TAMRA) until the probe is cleaved by the 5'
to 3' nuclease activity of the DNA polymerase during PCR
extension, causing release of a 5' reporter dye (6FAM).
60

Preferably, production of an amplicon causes emission of a

?uorescent signal that is detected by a CCD (charge-coupled
device) detection camera or other light capturing device, and
the amount of signal produced at a threshold cycle Within the

preferably a single-stranded oligodeoxyribonucleotide. The
appropriate length of a primer depends on the intended use
of the primer but typically ranges from about 10 to about 30

?uoresces When released from probe by hydrolytic activity
of DNA polymerase. Preferably, a quencher is attached to
the 3' end of the probe. A quencher is a ?uorescent molecule

detected, and nucleic acid controls. The exact siZe of an

The term “primer” refers to an oligonucleotide, Whether
natural or synthetic, capable of acting as a point of initiation
of DNA synthesis under conditions in Which synthesis of a
primer extension product complementary to a nucleic acid
strand is induced, i.e., in the presence of four different
nucleoside triphosphates and an agent for polymerization
(i.e., DNA polymerase or reverse transcriptase) in an appro
priate buffer and at a suitable temperature. A primer is

?uorogenic oligonucleotide probe (i.e., the hydrolysis or
TaqMan® probe) that anneals speci?cally Within the tem

knoWn analogs of natural nucleotides that can function in a
similar manner as naturally occurring nucleotides.
The term “oligonucleotide” refers to a molecule com
prised of tWo or more deoxyribonucleotides or ribonucle

tially identical thereto, respectively.

65

purely exponential phase of the PCR reaction, re?ects the
starting copy number of the target sequence being ampli?ed.
The invention also includes oligonucleotides substantially
identical to SEQ ID NOs: l-3. For example, oligonucleotide

US 7,332,597 B2
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5
sequences substantially identical to SEQ ID NOs: l-3 may
have several nucleotides added to or removed from their 5'
ends or several nucleotides added to or removed from their
3' ends. “Several nucleotides” in this context refers to about
3 nucleotides, or preferably about tWo nucleotides or more
preferably about one nucleotide. The person of skill in the art

— cont inued

5

SEQ

ID Sequence Substantially
NO: Identical to SEQ ID NO:

Will recognize that When adding nucleotides to the 5' and/or
3' ends SEQ ID NOs: 1-3 the identity of those nucleotides
may be dictated by the sequence of the MTB complex DNA
to be ampli?ed. HoWever, the skilled artisan may also Wish
to add overhangs to the 5' end of the forWard primer or 5' end
of the reverse primer (giving a 3' sticky end on the ampli
con). Such overhangs may include restriction enZyme sites
useful in providing sticky ends to facilitate subcloning of the

1

14 5 ' —GAAATTCGACAACAAAGTT

Notes

ECORI site added to

GGCCACCA-3 '

5'

end

Additionally, one of skill in the art Would envisage a
genus of sequences substantially identical to SEQ ID NO: 2

ampli?cation product, for example.
Primers and probes of the invention exhibit an absence of
hybridiZation to sequences contained in human RNA and

Wherein about one to about three nucleotides are added or

sets against human total nucleic acid under PCR conditions.

removed from the 5' end and/or about one to about three
nucleotides are added or removed from the 3' end, respec
tively, to include but not be limited to the folloWing exem

Additionally, the claims probes and primers lack cross

plary species:

DNA. This may be con?rmed theoretically by BLAST

analysis (NCBI), and empirically by testing selected primer
reactivity against other non-MTB complex pathogen
genomes that could be present in clinical samples. This may
also be con?rmed theoretically in a BLAST search, and

empirically using genomic material from non-MTB com

25

plex pathogen.

SEQ
ID Sequence Substantially
NO: Identical to SEQ ID NO:

For example, one of skill in the art Would envisage a
genus of sequences substantially identical to SEQ ID NO: 1

2

15 5 ' —TGGGACAACACCTGGAAC—3 '

Notes
2

nt

removed from

' 3

end

Wherein about one to about three nucleotides are added or 30

removed from the 5' end and/or about one to about three
nucleotides are added or removed from the 3' end, respec
tively, to include but not be limited to the folloWing exem

16 5 ' —GGACAACACCTGGAACAA—3 '

17 5 ‘ —GGACAACACCTGGAAC—3 ‘

removed from 5 '

2

nt

removed from 5 ‘

end and 2 nt
removed from

35
18 5 ' —GGGACAACACCTGGAACA—3 '

1 nt

1

‘3 end

removed from 5 '

end and 1 nt
removed from

SEQ
ID Sequence Substantially

4 5 ' —GACAACAAAGTTGGCCAC—3 '

nt

end

plary species:

NO: Identical to SEQ ID NO:

2

‘3 end

Notes
2

nt

removed from

' 3

40

19 5 ' —GGGACAACACCTGGAACAA—3 '

1 nt

removed from 5 '

end

end
20 5 ' —TGGGACAACACCTGGAACA—3 '
5 5 ' —CAACAAAGTTGGCCACCA—3 '

2

nt

removed from 5 '

6 5 ‘ —CAACAAAGTTGGCCAC—3 ‘

2

nt

removed from 5 ‘

end and 2 nt
removed from
'7 5 ' —ACAACAAAGTTGGCCACC—3 '

1 nt

8 5 ‘ —ACAACAAAGTTGGCCAC
CA-3 ‘

9 5 ‘ —GACAACAAAGTTGGCCA
CC-3 ‘

10 5 ' —CAACAAAGTTGGCCACC—3 '

1 nt removed from

CCA-3 ‘

13 5 ' —GACAACAAAGTTGGCCAC
CAA-3 '

50
23 5 ' —GTGGGACAACACCTGGAAC

‘ 3

end

nt

1 nt

1 nt

2

nt

' 3

removed from 5 '

24 5 ' —TGGGACAACACCTGGAACA

55
removed from 5 '

AG-3 '

25 5 ' —GAAATTCTGGGACAACACCTGG
AACAA-3 '

‘3 end

1 nt

‘3 end

removed from 5 '

end and 2 nt
removed from

AA-3 '

1 nt added to

‘3 end
5 v

end
1 nt added to

' 3

end
EcoRI site added to
5' end

removed from 5 '

end and 2 nt
removed from
12 5 ' —TGACAACAAAGTTGGCCA

22 5 ' —GGGACAACACCTGGAAC—3 '

1 nt removed from 5 ‘

2

21 5 ' —GGACAACACCTGGAACA—3 '

‘3 end

‘3 end

removed from

end and 1 nt
removed from

end

end and 1 nt
removed from
11 5 ' —ACAACAAAGTTGGCCAC—3 '

45

removed from 5 '

end and 1 nt
removed from

1 nt

end

end

added to

Finally, one of skill in the art Would envisage a genus of
‘3 end

sequences substantially identical to SEQ ID NO: 3 Wherein
about one to about three nucleotides are added or removed

5 '

end

1 nt added to

' 3

end

65

from the 5' end and/or about one to about three nucleotides
are added or removed from the 3' end, respectively, to

include but not be limited to the folloWing exemplary

species:

US 7,332,597 B2
8
to the probe, rather than identical, then it is useful to ?rst

establish the loWest temperature at Which only homologous
hybridization occurs With a particular concentration of salt
SEQ
ID Sequence Substantially
NO: Identical to SEQ ID NO:

(eg SSC or SSPE). Then assuming that 1% mismatching
3

26 5 ‘ —TTGGGTCCTGAGGCAACACT
C-3 ‘

27 5 ‘ —GGGTCCTGAGGCAACACTC
GG-3 ‘

28 5 ‘ —GGGTCCTGAGGCAACACTC—3 ‘

29 5‘ —TGGGTCCTGAGGCAACACT
CG-3‘

30 5‘ —TGGGTCCTGAGGCAACACTC
GG-3‘
31 5‘ —TTGGGTCCTGAGGCAACAC
TCG-3 ‘

32 5‘ —GGGTCCTGAGGCAACACT
CG-3‘

results in a 1° C. decrease in Tm, the temperature of the ?nal

Notes

2 nt removed from 5 ‘

Wash in the hybridization reaction is reduced accordingly
(for example, if sequences having >95% identity With the
probe are sought, the ?nal Wash temperature is decrease by
50 C.). In practice, the change in Tm can be between 05° C.

end

and 15° C. per 1% mismatch.

2 nt removed from

‘ 3

end

2

nt

end and 2 nt
removed from ‘3 end
1 nt removed from 5‘
end and 1 nt
removed from ‘3 end

0.2><SSC/0.1% SDS at room temperature. Moderately strin
gent conditions include Washing in 3><SSC at 42° C. The

parameters of salt concentration and temperature be varied
to achieve optimal level of identity betWeen the primer and
the target nucleic acid. Additional guidance regarding such
conditions is readily available in the art, for example,
Sambrook, Fischer and Maniatis, Molecular Cloning, a

1 nt removed from 5‘
end
1 nt removed from

‘3

end

20

end and 2 nt
removed from

Sons (1994).
The sequences 5'-CAACAAAGTTGGCCA-3' (SEQ ID
25

NO: 36) and 5'-CATGACAACAAAGTTGGCCA-3' (SEQ

30

tially similar to SEQ ID NO: 1. Additionally, 5'-GGTGG
GACAACACCTGGAAC-3' (SEQ ID NO: 38), 5'-ACAA
CACCTGGA-3'
(SEQ
ID
NO:
39),
and
5'-CAACACCTGGAA-3' (SEQ ID NO: 40) are explicitly

ID NO: 37) are explicitly excluded as sequences substan
‘3 end

1 nt added to 5‘

end
35 5‘ —TTGGGTCCTGAGGCAACACTC
GGA-3 ‘

1 nt added to

laboratory manual, (2nd ed.), Cold Spring Harbor Labora
tory Press, NeW York, (1989) and F. M. Ausubel et al eds.,
Current Protocols in Molecular Biology, John Wiley and

2 nt removed from 5‘
end and 1 nt
removed from ‘3 end

33 5‘ —TGGGTCCTGAGGCAACACTC—3 ‘ 1 nt removed from 5‘

34 5‘ —GTTGGGTCCTGAGGCAACAC

Stringent conditions involve hybridizing at 68° C. in
5><SSC/5>< Denhart’s solution/1.0% SDS, and Washing in

removed from 5 ‘

‘3

excluded as sequences substantially similar to SEQ ID NO:
2.
Another aspect of the invention relates to a kit for

end

The skilled artisan Will also appreciate that oligonucle
otide sequences substantially identical to SEQ ID NOs: 1-3
may differ from SEQ ID NOs: 1-3, respectively, With respect
to the identity of at least one nucleotide base. However, all

detecting MTB complex DNA having SEQ ID NOs: 1 and
35

PCR and includes SEQ ID NO: 3 or a oligonucleotides

substantially identical thereto.

oligonucleotides sequences substantially identical to SEQ
ID NOs: 1-3 Will hybridize under stringent conditions (as
de?ned herein) to all or a portion of the complements of

Another aspect of the invention relates to a method of
40

SEQ ID NOs: 1-3 (i.e., target sequences), respectively. The
terms “hybridize(s) speci?cally” or “speci?cally
hybridize(s)” refer to complementary hybridization betWeen
an oligonucleotide (e.g., a primer or labeled probe) and a
target sequence. The term speci?cally embraces minor mis
matches that can be accommodated by reducing the strin
gency of the hybridization media to achieve the desired

sample.
45

50

hybridization of nucleic acids having 3 or more mismatches
out of 20 contiguous nucleotides, more preferably 2 or more
55

ably one or more mismatch out of 20 contiguous nucle

otides. The hybridizing portion of the hybridizing nucleic

perature (Tm), Which is the temperature at Which the probe
dissociates from the target DNA. This melting temperature
is used to de?ne the required stringency conditions. If
sequences are to be identi?ed that are substantially identical

serum, sputum, stool, urine, semen, pericardial ?uid,

nasopharyngeal/throat sWabs, cerebrospinal ?uid (CSF),

complementary, i.e., substantially identical nucleic acid
sequences, hybridize. Preferably, such conditions prevent

acid is at least about 90%, preferably at least about 95%, or
most preferably about at least about 98%, identical to the
sequence of a target sequence, or its complement.
Hybridization of a nucleic acid to a nucleic acid sample
under stringent conditions is de?ned beloW. Nucleic acid
duplex or hybrid stability is expressed as a melting tem

The present methods and oligonucleotides can be applied
to any type of biological sample that is suspected of con

taining MTB complex DNA. The term “biological sample”
refers to a sample comprising any biological material (e.g.,
biological ?uids or tissues) containing nucleic acids. Bio
logical samples can include tissue samples, Whole blood or

priming for the PCR polymerases or detection of hybridiza

mismatches out of 20 contiguous nucleotides, most prefer

detecting MTB complex DNA by using SEQ ID NOs: 1 and
2; or oligonucleotides substantially identical thereto, in a
polymerase chain reaction performed on a biological

tion signal.

Under stringent hybridization conditions, only highly

2 or oligonucleotides substantially identical thereto. One
embodiment of this aspect of the invention utilizes real-time

amniotic ?uid and the like. Alternatively, tissues may, for
example, be surgically resected from a patient in the form of
a biopsy or autopsy tissue sample. Preferably, at least about
50 mg of tissue is resected.
Most preferably, the tissue to be analyzed is in the form
of, or contains a granuloma. Preferably, granulomas are

aggregates of particular types of chronic in?amatory cells
60

Which form nodules in the millimeter size range. Granulo
mas may be con?uent, forming larger areas. Granuloma

have collections of modi?ed macrophages, termed epithe
lioid cells, usually With a surrounding zone of lymphocytes.
65

Epithelioid cells are so named by tradition because of their
histological resemblance to epithelial cells, but are not in
fact epithelial; they are derived from blood monocytes, like
all macrophages. Epithelioid cells are less phagocytic than
other macrophages and appear to be modi?ed for secretory

US 7,332,597 B2
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functions. Macrophages in granulomas are commonly fur

alcoholic solutions of decreasing concentration. Altema

ther modi?ed to form multinucleate giant cells. These arise

tively, the sample is simultaneously deparaf?nized and rehy

by fusion of epithelioid macrophages Without nuclear or
cellular division forming huge single cells Which may con

drated.

tain dozens of nuclei. In some circumstances the nuclei are

isolated from the rehydrated tissue. Deparaf?nized samples

arranged around the periphery of the cell, termed a Lang
hans-type giant cell (characteristically seen in tuberculosis);

can be homogenized using mechanical, sonic or other means
of homogenization, eg by laser microdisection. In one

in other circumstances the nuclei are randomly scattered

embodiment, rehydrated samples are homogenized in a
solution comprising a chaotropic agent, such as guanidinium

Once the sample is reyhdrated, DNA is extracted and

throughout the cytoplasmifor example in the foreign body
type of giant cell Which is formed in response to the presence
of other indigestible foreign material in the tissue. Areas of

thiocyanate (also sold as guanidinium isothiocyanate).

granulomatous in?ammation commonly undergo necrosis.

compounds, urea, formamide, potassium iodiode, potassium

The prototype example here is caseous necrosis in tubercu
losis.
Generally microscale amounts of tissue are needed to
detect MTB complex DNA. Preferably, a scrape of tissue

thiocyantate and similar compounds. The preferred chaotro

from a pathological sample is used. More preferably, for

Many anionic counterions are useful, and one of skill in the
art can prepare many guanidinium salts With such appropri
ate anions. The effective concentration of guanidinium solu
tion used in the invention generally has a concentration in
the range of about 1 to about 5M With a preferred value of

malin-?xed and paraffin-embedded tissues are sectioned at a
thickness of a 3 to 4 um, and nucleic acids are isolated from
a 0.2 cm by 0.2 cm area of the tissue section.

Chaotropic agents include but not limited to: guanidinium
pic agent for the methods of the invention is a guanidinium
compound, such as guanidinium isothiocyanate (also sold as

guanidinium thiocyanate) and guanidinium hydrochloride.

20

To amplify a target nucleic acid sequence in a sample by
PCR, the sequence must be accessible to the components of

the ampli?cation system. In general, this accessibility is
ensured by isolating the nucleic acids from the sample. A
variety of techniques for extracting nucleic acids, in par
ticular deoxyribonucleic acids, from biological samples are
knoWn in the art. Alternatively, if the sample is fairly readily

25

buffered to a pH of about 3 to about 6, more preferably about
4, With a suitable biochemical bulfer such as Tris-Cl. The

chaotropic solution may also contain reducing agents, such
as dithiothreitol (DTT), ([3-mercaptoethanol; BME); and

disruptable, the nucleic acid need not be puri?ed prior to

ampli?cation by the PCR technique, i.e., if the sample is

comprised of cells, particularly peripheral blood lympho

about 4M. If RNA is already in solution, the guanidinium
solution may be of higher concentration such that the ?nal
concentration achieved in the sample is in the range of about
1 to about 5M. The guanidinium solution also is preferably

30

combinations thereof. The chaotropic solution may also

cytes or monocytes, lysis and dispersion of the intracellular

contain RNAse and/or DNAase inhibitors.

components may be accomplished merely by suspending the

Commercially available kits are also readily available to
isolate nucleic acids from various tissues. For example, such
kits are available from Qiagen, Inc. (Valencia, Calif.).
DNA is then recovered from the solution by, for example,

cells in hypotonic buffer.
If it is not possible to extract DNA from the tissue sample
soon after its resection, the sample may be ?xed or frozen.
DNA extracted and isolated from frozen or fresh samples of
resected tissue is extracted by any method knoWn in the art,

for example, Sambrook, Fischer and Maniatis, Molecular
Cloning, a laboratory manual, (2nd ed.), Cold Spring Harbor
Laboratory Press, NeW York, (1989). Preferably, care is

35

phenol chloroform extraction, ion exchange chromatogra
phy or size-exclusion chromatography. DNA may then be

further puri?ed using the techniques of extraction, electro
phoresis, chromatography, precipitation or other suitable
40

total DNA from a fresh, frozen or ?xed biological sample is

process.

preferably carried out using polymerase chain reaction

Alternatively, tissue obtained from the patient may be

?xed, preferably by formalin (formaldehyde) or gluteralde
hyde treatment, for example. Biological samples ?xed by

(PCR) methods common in the art. The ?rst step of each
45

alcohol immersion are also contemplated in the present

invention. Fixed biological samples are often dehydrated
and embedded in paraf?n or other solid supports knoWn to
those of skill in the art. Such solid supports are envisioned

to be removable With organic solvents, alloWing for subse

techniques.
The ampli?cation of MTB complex DNA from isolated

taken to avoid degradation of DNA during the extraction

cycle of the PCR involves the separation of the nucleic acid
duplex formed by the primer extension. Once the strands are
separated, the next step in PCR involves hybridizing the
separated strands With primers that ?ank the target sequence
e.g. SEQ ID NOs: l and 2. The primers are then extended to

quent rehydration of preserved tissue. Fixed and paraffin

form complementary copies of the target strands. For suc
cessful PCR ampli?cation, the primers are designed so that

embedded (FPE) tissue specimen as described herein refers

the position at Which each primer hybridizes along a duplex

50

sequence is such that an extension product synthesized from

to storable or archival tissue samples.

one primer, When separated from the template (comple

DNA may be extracted from the FPE specimen by any of
the methods as described in US. Pat. No. 6,428,963, Which

55

is hereby incorporated by reference in its entirety. Most

ment), serves as a template for the extension of the other

primer. The cycle of denaturation, hybridization, and exten

preferably, total DNA is extracted from granulomas from a

sion is repeated as many times as necessary to obtain the

formalin-?xed and paraffin-embedded tissue specimen.

desired amount of ampli?ed nucleic acid. Strand separation
is achieved by heating the reaction to a suf?ciently high

In an embodiment of the invention, DNA is isolated from
an archival pathological sample or biopsy Which is ?rst

deparaf?nized. An exemplary deparaf?nization method

temperature for a suf?cient time to cause the denaturation of
the duplex but not to cause an irreversible denaturation of

involves Washing the paraf?nized sample With an organic
solvent, such as xylene. Deparaf?nized samples can be

the polymerase (see US. Pat. No. 4,965,188). Template
dependent extension of primers in PCR is catalyzed by a

60

polymerizing agent in the presence of adequate amounts of

rehydrated With an aqueous solution of a loWer alcohol.

Suitable loWer alcohols, for example include, methanol,
ethanol, propanols, and butanols. Deparaf?nized samples
may be rehydrated With successive Washes With loWer

65

four deoxyribonucleoside triphosphates (typically dATP,
dGTP, dCTP, dUTP and dTTP) in a reaction medium com

prised of the appropriate salts, metal cations, and pH bulf

US 7,332,597 B2
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ering system. Suitable polymerizing agents are enzymes
known to catalyze template-dependent DNA synthesis. For
example, Thermus lhermophilus (Tth) DNA polymerase, a
therrnostable DNA polymerase by Roche Molecular Sys

samples in parallel. Preferably, SEQ ID NO: 1 or an oligo
nucleotide substantially identical thereto is used as the
forWard primer and SEQ ID NO: 2 or an oligonucleotide
substantially identical thereto is used as the reverse primer.

tems (Alameda, Calif.) PCR is most usually carried out as an
automated process With a therrnostable enzyme. In this

A decrease in ampli?cation product in the nucleic acid

process, the temperature of the reaction mixture is cycled

amount of ampli?cation product in the nucleic acid sample

through a denaturing region, a primer annealing region, and
an extension reaction region automatically. Equipment spe
ci?cally adapted for this purpose is commercially available

pound is capable of inhibiting MTB complex pathogen

sample derived from the treated tissue culture relative to an
derived from the control indicates that a candidate com

groWth. MTB complex pathogen may be cultured in

from Roche Molecular Systems.
Most preferably, ampli?cation of MTB complex DNA

MB/BacT bottle according to manufacturer instruction or on

RNA is carried out using a ?uorescence based real-time

More preferably, the tissue culture comprises the human
alveolar epithelial cell line A549. Additionally, the term

LoWeinstein-Jensen (LI) slants prepared media (Oxoid).

detection method (e.g. SmartCycler®, Cepheid, or the ABI
PRISM 7700 or 7900 Sequence Detection System [Taq

“tissue culture” as used herein is not limited to in vitro uses.
The term also encompasses live animals that act as incuba

Man®], Applied Biosystems, Foster City, Calif.) or similar

tors for MTB complex pathogen groWth such as suckling

system as described by Heid et al., (Genome Res 1996;
61986-994) and Gibson et al.(Genome Res 1996; 6:995
1001). This methodology is also referred to interchangeably
herein as “real-time PCR” or “Q-PCR” Where “Q” stands for

mice, rats or other mammals.

Additional advantages of the present invention Will
20

become readily apparent to those skilled in this art from the

25

embodiment of the invention is shoWn and described, simply
by Way of illustration of the best mode contemplated of
carrying out the invention. As Will be realized, the invention
is capable of other and different embodiments, and its

30

several details are capable of modi?cations in various obvi
ous respects, all Without departing from the invention. The
present invention may be practiced Without some or all of
these speci?c details. In other instances, Well knoWn process
operations have not been described in detail, in order not to

folloWing detailed description, Wherein only the preferred

quanitative. The output of the ABI 7700 (TaqMan® Instru
ment) is expressed in CT’s or “cycle thresholds”. A higher
number of target molecules in a sample generates a signal
With feWer PCR cycles (loWer CT) than a sample With a

loWer number of target molecules (higher CT). By extension,
given a set number of cycles, the level of ?uorescence
generated in the reaction Will be indicative of the amount of
ampli?cation product Which in turn, is a function of the

amount template nucleic acid in the original biological
sample. Therefore, real-time PCR also alloWs for the quan
ti?cation of template DNA in the original biological sample.

unnecessarily obscure the present invention. Accordingly,

Preferably, the hydrolysis or TaqMan® probe for the oligo

the draWings and description are to be regarded as illustra

nucleotide primer pair SEQ ID NO: 1 and 2, is SEQ ID NO:

tive in nature, and not as restrictive.

3.

One of skill Will recognize, hoWever, that the oligonucle

EXAMPLE 1

35

otides of the invention are useful for quantifying MTB

Mycobacterial DNA extraction procedure (Epicenter
Technologies MasterPure Puri?cation Kit Masidon, Wis.)

complex DNA by any knoWn method, such as ligase chain
reaction (LCR) or self-sustained sequence replication, each

of Which provides su?icient ampli?cation. Additionally, the
present invention envisages the quanti?cation of MTB DNA

40

1. Control strains of mycobacteria Were groWn on L]
slants Were ?xed in 10% Formalin for at least 1 Week before

via use of a PCR-free system employing, for example
?uorescent labeled probes similar to those of the Invader®

processing.

Assay (Third Wave Technologies, Inc.).

transfer pipettes into a 50 ml conical tube.
3. The slants Were Washed 3 times With sterile saline, each
time the saline being transferred into 50 ml conical tubes.
4. The ?nal aliquot of saline Was added to the slant, and

As used herein, a “intemal control DN

2. The formalin Was then aspirated off using sterile plastic

is meant to

include DNA Whose presence in a biological sample enables
an assessment of MTB complex DNA levels. Preferably,

45

ampli?cation of MTB complex DNA in a biological sample

the organism groWth Was scraped from the surface and
suspended in the saline.

is conducted in parallel, ie at the same time, With ampli
?cation of internal control DNA. This alloWs for a determi
nation of the overall amount of DNA in the sample and a
control for variations in DNA recovery. “Intemal controls”
can include, but are not limited to the cyclophilin gene,

[3-actin gene, the transferrin receptor gene, GAPDH gene,
and the like. Most preferably, the internal control DNA is a
portion of the GAPDH gene.

5. The suspension Was alloWed to rest for at least 10
50

Was transferred to 2 ml conical tubes

7. The mycobacteria Were alloWed to settle out overnight.
55

Another aspect of the invention relates to a method of

60

With a compound suspected of being capable of inhibiting

pound. Next, PCR is performed on both nucleic acid

9. The tubes Were incubated for 20 minutes at 680 C.,

inverting the tubes tWice during the heating process.
10. The tubes Were chilled on ice for 5 minutes
11. 450 uL of MCP solution Was added to each tube and

MTB complex pathogen groWth. Next nucleic acids are
isolated from the portion of the infected tissue culture
contacted by the candidate compound. As a control, nucleic
acids are also isolated from a portion of the remainder of the
infected tissue culture not contacted by the candidate com

8. Still under the biological safety cabinet, the saline Was
aspirated from the pellet and the solubilizing agent Was
added to the tubes. Each tube contained the folloWing:
a. 900 uL of 2x Tissue and Cell Lysis buffer
b. 6 uL of Proteinase K (50 uG/mL)

identifying compounds capable of inhibiting the groWth of
MTB complex pathogen. The method generally entails
infecting a tissue culture With an MTB complex pathogen
and then contacting a portion of the infected tissue culture

minutes to alloW the larger particles to precipitate.
6. The remaining ?uid containing the ?xed mycobacteria

65

the tubes vortexed
12. The tubes Were then centrifuged in the microfuge
13. The supernatant Was transferred into a clean

microfuge tube

US 7,332,597 B2
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14.
tubes
15.
16.
17.

of the real-time quantitative PCR assay using the primer pair

500 uL of isopropanol Was added to each tube and the
inverted 30-40 times
The tubes Were frozen over night at —200 C.
The DNA Was pelleted for 10 minutes in a microfuge
The DNA pellet Was rinsed With 75% EtOH

SEQ ID NOs: 1 and 2 With the probe SEQ ID NO: 3, Were
correlated the culture results for the ?xed tissue samples.
GAPDH DNA Was used as an internal control for the assay

performed on the ?xed tissue samples.

18. The pellet Was drained and dried thoroughly

Results: All serial dilutions of MTB complex DNA Were

19. The DNA Was resuspended in 35 uL of TE Buifer
The DNA Was frozen at —200 C. until used for PCR

positive by this assay, including the highest dilution With

ampli?cation. Atypical (non-TB) mycobacterial strains used
as negative controls:
Mycobaclerium marinum ATCC 927
M
M
M
M

10

avium ATCC 25291
cheloneae ATCC 19233
inlracullulare ATCC 13950
kansasii ATCC 12498

only one copy of MTB complex DNA. FIG. 2. There Was no
cross reactivity With other mycobacterial or human DNA.
FIG. 3. All cases positive for MTB by PCR on ?xed tissue
sections Were also positive by culture. No MTB culture
positive cases Were missed by the assay. All cases negative
for MTB by PCR on ?xed tissue sections Were also negative

for the organism complex by culture. FIGS. 4 and 5.
Conclusion: The real-time quantitative PCR assay is
rapid, speci?c and highly sensitive for identi?cation of MTB
in formalin-?xed paraffin-embedded tissue sections. It is
technically simple and can be used in routine pathology

M forluilum ATCC 6841
M cheloneae subspecies abscessus CDC strain from 2001
M Zerrae UK strain from 1988

M gordonae ATCC 14470
20

practice.
In this disclosure there is described only the preferred

EXAMPLE 2

Design: Serial dilutions of formalin-?xed MTB complex
DNA, other mycobacterial DNA and DNA from microdis
sected formalin-?xed paraffin-embedded tissue sections
diagnosed as necrotizing granulomatous in?ammation With
acid-fast bacilli Were used as templates for a PCR assay.

Serial dilutions of ?xed MTB complex DNA Were prepared
such that the highest dilution had only one copy of MTB
complex DNA. The ?xed tissue sections used Were selected
such that culture results Were available for each case. Results

25

embodiments of the invention and but a feW examples of its
versatility. It is to be understood that the invention is capable
of use in various other combinations and environments and
is capable of changes or modi?cations Within the scope of
the inventive concept as expressed herein. Thus, for
example, those skilled in the art Will recognize, or be able to
ascertain, using no more than routine experimentation,
numerous equivalents to the speci?c substances and proce
dures described herein. Such equivalents are considered to
be Within the scope of this invention.

SEQUENCE LISTING

SEQ ID NO 1
LENGTH: 20
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Chemically synthesized
<400> SEQUENCE:

l

gacaacaaag ttggccacca

SEQ ID NO 2
LENGTH: 20
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Chemically synthesized
<400> SEQUENCE: 2

tgggacaaca cctggaacaa

SEQ ID NO 3
LENGTH: 23
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Chemically synthesized
<400> SEQUENCE: 3

ttgggtcctg aggcaacact cgg

23
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—cont inued

SEQ ID NO 4
LENGTH: 18
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Chemically synthesized
SEQUENCE: 4

gacaacaaag ttggccac

SEQ ID NO 5
LENGTH: 18
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Chemically synthesized
SEQUENCE: 5

caacaaagtt ggccacca

SEQ ID NO 6
LENGTH: 16
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Chemically synthesized
SEQUENCE: 6

caacaaagtt ggccac

SEQ ID NO '7
LENGTH: 18
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Chemically synthesized
SEQUENCE: '7

acaacaaagt tggccacc

SEQ ID NO 8
LENGTH: 19
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Chemically synthesized
SEQUENCE: 8

acaacaaagt tggccacca

SEQ ID NO 9
LENGTH: 19
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Chemically synthesized
SEQUENCE: 9

gacaacaaag ttggccacc

SEQ ID NO 10
LENGTH: 17
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:

US 7,332,597 B2
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—cont inued

<223> OTHER INFORMATION: Chemically synthesized
<400> SEQUENCE: lO

caacaaagtt ggccacc

<2lO> SEQ ID NO 11
<2ll> LENGTH: 17

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<400> SEQUENCE: ll

acaacaaagt tggccac

<2lO> SEQ ID NO 12
<2ll> LENGTH: 21
<2l2> TYPE: DNA

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<400> SEQUENCE: l2

tgacaacaaa gttggccacc a

21

<2lO> SEQ ID NO 13
<2ll> LENGTH: 21
<2l2> TYPE: DNA

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<400> SEQUENCE: l3
gacaacaaag ttggccacca a

21

<2lO> SEQ ID NO 14
<2ll> LENGTH: 26
<2l2> TYPE: DNA

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<400> SEQUENCE: l4

gaattcgaca acaaagttgg ccacca

<2lO> SEQ ID NO 15
<2ll> LENGTH: 18

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<400> SEQUENCE: l5

tgggacaaca cctggaac

<2lO> SEQ ID NO 16
<2ll> LENGTH: 18

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<400> SEQUENCE: l6

ggacaacacc tggaacaa

26

US 7,332,597 B2
19

20
—cont inued

<2lO> SEQ ID NO 17
<2ll> LENGTH: 16
<2l2> TYPE: DNA

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<400> SEQUENCE: l7

ggacaacacc tggaac

l6

<2lO> SEQ ID NO 18
<2ll> LENGTH: 18

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<400> SEQUENCE: l8

gggacaacac ctggaaca

l8

<2lO> SEQ ID NO 19
<2ll> LENGTH: 19

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<400> SEQUENCE: l9

gggacaacac ctggaacaa

l9

<2lO> SEQ ID NO 20
<2ll> LENGTH: 19

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<400> SEQUENCE: 2O

tgggacaaca cctggaaca

l9

<2lO> SEQ ID NO 21
<2ll> LENGTH: 17

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<400> SEQUENCE: 21

ggacaacacc tggaaca

l7

<2lO> SEQ ID NO 22
<2ll> LENGTH: 17

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<400> SEQUENCE: 22

gggacaacac ctggaac

<2lO> SEQ ID NO 23
<2ll> LENGTH: 21

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized

l7
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<400> SEQUENCE: 23

gtgggacaac acctggaaca a

21

<210> SEQ ID NO 24
<211> LENGTH: 21
<212> TYPE: DNA

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<400> SEQUENCE: 24

tgggacaaca cctggaacaa g

21

<210> SEQ ID NO 25
<211> LENGTH: 26
<212> TYPE: DNA

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<400> SEQUENCE: 25

gaattctggg acaacacctg gaacaa

26

<210> SEQ ID NO 26
<211> LENGTH: 21
<212> TYPE: DNA

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<400> SEQUENCE: 26

ttgggtcctg aggcaacact c

21

<210> SEQ ID NO 27
<211> LENGTH: 21
<212> TYPE: DNA

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<400> SEQUENCE: 2'7

gggtcctgag gcaacactcg g

21

<210> SEQ ID NO 28
<211> LENGTH: 19
<212> TYPE: DNA

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<400> SEQUENCE: 28

gggtcctgag gcaacactc

19

<210> SEQ ID NO 29
<211> LENGTH: 21
<212> TYPE: DNA

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<400> SEQUENCE: 29

tgggtcctga ggcaacactc g

<210> SEQ ID NO 30
<211> LENGTH: 22

21
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23
—cont inued
<2l2> TYPE:

DNA

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<400> SEQUENCE: 3O

tgggtcctga ggcaacactc gg

22

<2lO> SEQ ID NO 31
<2ll> LENGTH: 22
<2l2> TYPE: DNA

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<400> SEQUENCE: 31

ttgggtcctg aggcaacact cg

22

<2lO> SEQ ID NO 32
<2ll> LENGTH: 20

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<400> SEQUENCE: 32

gggtcctgag gcaacactcg

<2lO> SEQ ID NO 33
<2ll> LENGTH: 20

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<400> SEQUENCE: 33

tgggtcctga ggcaacactc

<2lO> SEQ ID NO 34
<2ll> LENGTH: 24

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<400> SEQUENCE: 34

gttgggtcct gaggcaacac tcgg

24

<2lO> SEQ ID NO 35
<2ll> LENGTH: 24

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<400> SEQUENCE: 35

ttgggtcctg aggcaacact cgga

<2lO> SEQ ID NO 36
<2ll> LENGTH: 15

<2l3> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: Chemically synthesized
<400> SEQUENCE: 36

24
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26
—cont inued

caacaaagtt ggcca

15

SEQ ID NO 37
LENGTH: 20
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Chemically synthesized
<400> SEQUENCE:

3'7

catgacaaca aagttggcca

SEQ ID NO 38
LENGTH: 20
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Chemically synthesized
<400> SEQUENCE:

38

ggtgggacaa cacctggaac

SEQ ID NO 39
LENGTH: 12
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Chemically synthesized
<400> SEQUENCE:

39

acaacacctg ga

l2

SEQ ID NO 40
LENGTH: 12
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Chemically synthesized
<400> SEQUENCE:

4O
12

caacacctgg aa

What is claimed is:

45

and a second oligonucleotide selected from an oligonucle

otide consisting essentially of SEQ ID NO:4l or SEQ ID

1. An isolated oligonucleotide consisting of SEQ ID NO:

NOz43.

1

2. An isolated oligonucleotide consisting of SEQ ID NO:
2

50

3. An isolated oligonucleotide consisting of SEQ ID NO:

42, Wherein the oligonucleotide is capable of amplifying
MTB complex DNA When used in conjunction With SEQ ID
NO: 1 in a polymerase chain reaction.

4. An isolated oligonucleotide capable of being a hydroly
sis probe for the oligonucleotide primer pair of SEQ ID
NOs: l and 2, Wherein said oligonucleotide consists of the
sequence of SEQ ID NO: 3 or SEQ ID NO: 43.
5. A kit for detecting MTB complex DNA comprising a
?rst isolated oligonucleotide consisting of SEQ ID NO: 1
and a second oligonucleotide selected from an oligonucle
otide consisting essentially SEQ ID NO: 41 or SEQ ID NO:
42.

6. A kit for detecting MTB complex DNA comprising a
?rst isolated oligonucleotide consisting of SEQ ID NO: 2

7. A kit for detecting MTB complex DNA comprising a
?rst isolated oligonucleotide consisting of SEQ ID NO: 1
and a second oligonucleotide consisting of SEQ ID NO: 2.
8. A kit for detecting MTB complex DNA comprising a
?rst oligonucleotide selected from the group consisting of:
(A) an isolated oligonucleotide consisting of the sequence
SEQ ID NO: 1;
(B) and a second oligonucleotide selected from the group

consisting of:
60

1. an isolated oligonucleotide consisting of SEQ ID
NO: 2;
2. an isolated oligonucleotide consisting of 14 to 26

nucleotides,
Wherein said oligonucleotide hybridizes the complement
65

of a sequence consisting of SEQ ID NO: 2 under

stringent conditions, Wherein said oligonucleotide is
capable of amplifying MTB complex DNA When used
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in conjunction With SEQ ID NO: 1 in a polymerase

28
9. The kit of claims 7 or 8 further comprising a third

chain reaction; and
isolated oligonucleotide consisting of SEQ ID NO: 3 or SEQ
3. an isolated oligonucleotide consisting of SEQ ID
ID NO: 43.
NO: 42, and Wherein the oligonucleotide is capable
10. The kit of claims 7 or 8 further comprising a PCR
of amplifying MTB complex DNA When used in 5 reaction bulTer and DNA polymerase enzyme.
conjunction With SEQ ID NO: 1 in a polymerase
chain reaction.
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